Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.

Autor: Liu H; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China., He J; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bagheri-Yarmand R; Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Li Z; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu R; Cancer Research Center, School of Medicine, Xiamen University, Xiamen, China., Wang Z; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bach DH; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA., Huang YH; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA., Lin P; Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Guise TA; Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gagel RF; Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. rfgagel@gmail.com., Yang J; Houston Methodist Cancer Center, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA. jyang2@houstonmethodist.org.; Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jyang2@houstonmethodist.org.

Publikováno v: Nature communications [Nat Commun] 2022 Jun 27; Vol. 13 (1), pp. 3684. Date of Electronic Publication: 2022 Jun 27.

ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET , VEGFR2 , and IGFBP2 .

Autor: Bagheri-Yarmand R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. ryarmand@mdanderson.org., Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ye L; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Shiny Jebaraj Y; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Martinez JA; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ma J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tarapore RS; Oncoceutics, Inc., Philadelphia, Pennsylvania., Allen JE; Oncoceutics, Inc., Philadelphia, Pennsylvania., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas., Williams MD; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gagel RF; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 665-675. Date of Electronic Publication: 2021 Feb 03.

Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).

Autor: Stanescu, Laura-Semonia^1,2 (AUTHOR) adina.ghemigian@umfcd.ro, Ghemigian, Adina^2,3 (AUTHOR) carsote_m@hotmail.com, Ciobica, Mihai-Lucian^4,5 (AUTHOR) lucian.ciobica@umfcd.ro, Nistor, Claudiu^6,7 (AUTHOR) adrian.ciuche@umfcd.ro, Ciuche, Adrian^6,7 (AUTHOR), Radu, Andreea-Maria^8,9 (AUTHOR) andreea.radu@rez.umfcd.ro, Sandru, Florica^8,9 (AUTHOR) florica.sandru@umfcd.ro, Carsote, Mara^2,3 (AUTHOR)

Publikováno v: International Journal of Molecular Sciences. Sep2024, Vol. 25 Issue 18, p9765. 21p.

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

Autor: Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ.

Publikováno v: Journal of clinical oncology (2012).
info:cnr-pdr/source/autori:Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ./titolo:Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial./doi:/rivista:Journal of clinical oncology/anno:2012/pagina_da:/pagina_a:/intervallo_pagine:/volume

PURPOSE: There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::effe6130d25aba058e81cff931780bcd
https://publications.cnr.it/doc/208548

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs.

Autor: Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX, USA., Bagheri-Yarmand R; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX, USA., Ringel MD; Division of Endocrinology, Diabetes and Metabolism, The Ohio State University College of Medicine, Columbus, OH, USA., Grubbs EG; Department of Surgical Oncology, The University of Texas MD Anderson Cancer, Houston, TX, USA., Zafereo M; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer, Houston, TX, USA., Cote G; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX, USA., Gagel RF; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX, USA., Robinson BG; Northern Clinical School, Kolling Institute of Medical Research, The University of Sydney School of Medicine, Sydney, Australia., Shaw KR; Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX., Hu MI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer, Houston, TX, USA.

Publikováno v: Endocrine-related cancer [Endocr Relat Cancer] 2020 Aug; Vol. 27 (8), pp. T27-T39.